567 related articles for article (PubMed ID: 32871009)
1. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
Withaar C; Meems LMG; Markousis-Mavrogenis G; Boogerd CJ; Silljé HHW; Schouten EM; Dokter MM; Voors AA; Westenbrink BD; Lam CSP; de Boer RA
Cardiovasc Res; 2021 Jul; 117(9):2108-2124. PubMed ID: 32871009
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
Shi L; Zhu D; Wang S; Jiang A; Li F
Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
6. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
7. Exogenous supplement of glucagon like peptide-1 protects the heart against aortic banding induced myocardial fibrosis and dysfunction through inhibiting mTOR/p70S6K signaling and promoting autophagy.
Zheng RH; Zhang WW; Ji YN; Bai XJ; Yan CP; Wang J; Bai F; Zhao ZQ
Eur J Pharmacol; 2020 Sep; 883():173318. PubMed ID: 32621911
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.
Gaspari T; Brdar M; Lee HW; Spizzo I; Hu Y; Widdop RE; Simpson RW; Dear AE
Diab Vasc Dis Res; 2016 Jan; 13(1):56-68. PubMed ID: 26408644
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
[TBL] [Abstract][Full Text] [Related]
10. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.
Wang X; Ding Z; Yang F; Dai Y; Chen P; Theus S; Singh S; Budhiraja M; Mehta JL
Clin Sci (Lond); 2016 Aug; 130(15):1353-62. PubMed ID: 27129181
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fraction.
Kanashiro-Takeuchi RM; Takeuchi LM; Dulce RA; Kazmierczak K; Balkan W; Cai R; Sha W; Schally AV; Hare JM
Am J Physiol Heart Circ Physiol; 2023 Jun; 324(6):H739-H750. PubMed ID: 36897749
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
13. Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype.
Li Y; Kubo H; Yu D; Yang Y; Johnson JP; Eaton DM; Berretta RM; Foster M; McKinsey TA; Yu J; Elrod JW; Chen X; Houser SR
Am J Physiol Heart Circ Physiol; 2023 Apr; 324(4):H443-H460. PubMed ID: 36763506
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
Alex L; Russo I; Holoborodko V; Frangogiannis NG
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.
Chang D; Xu TT; Zhang SJ; Cai Y; Min SD; Zhao Z; Lu CQ; Wang YC; Ju S
Exp Biol Med (Maywood); 2021 Dec; 246(23):2511-2521. PubMed ID: 34342551
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
[TBL] [Abstract][Full Text] [Related]
18. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
[TBL] [Abstract][Full Text] [Related]
19. Myocardial reverse remodeling: how far can we rewind?
Rodrigues PG; Leite-Moreira AF; Falcão-Pires I
Am J Physiol Heart Circ Physiol; 2016 Jun; 310(11):H1402-22. PubMed ID: 26993225
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet.
Sukumaran V; Tsuchimochi H; Sonobe T; Waddingham MT; Shirai M; Pearson JT
Cardiovasc Diabetol; 2020 Feb; 19(1):24. PubMed ID: 32093680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
